Physician profile
Michael J Finger
NPI 1609858091
$3,017.18
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $211 · 2021: $361 · 2022: $214 · 2023: $642 · 2024: $99.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $494 · Food and Beverage: $148 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $493.81 |
| Food and Beverage | $148.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,021.37 | 2019 | |
| Astellas Pharma US INC | $919.42 | 2019-2023 | Myrbetriq |
| Procept Biorobotics Corporation | $518.18 | 2022-2023 | Aquabeam Robotic System |
| Urovant Sciences INC | $136.38 | 2021-2022 | |
| Healthtronics Stone Solutions, LLC | $83.18 | 2019 | |
| Tolmar, INC. | $66.31 | 2023-2024 | |
| Tolmar Pharmaceuticals, INC. | $63.67 | 2019-2022 | |
| Pfizer INC. | $45.50 | 2019-2024 | |
| Travere Therapeutics, INC. | $33.15 | 2019-2022 | |
| Medtronic USA, INC. | $28.27 | 2019 | |
| Merck Sharp & Dohme LLC | $21.24 | 2024 | Welireg, Keytruda |
| 180 Medical, INC. | $19.00 | 2024 | Gentlecath |
| Allergan, INC. | $18.08 | 2021 | |
| Axonics, INC. | $15.24 | 2022 | |
| Medtronic, INC. | $14.46 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Finger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.